|
IFN-g |
Plasmodium chabaudi adami 556KA |
CBA/CaH |
rIFN-g |
no |
no |
N.I. |
N.I. |
Delayed onset and decreased peak |
Resistant to secondary infection |
Clark et al., 1987, J Immunol |
Link |
|
IFN-g |
Plasmodium chabaudi adami 556KA |
129/Sv x C57BL/6 (WT = 129/Ola) |
IFN-g -/- |
no |
no |
N.I. |
N.I. |
Delayed clearance |
N.I. |
Van der heyde et al., 1997, Exp Parasitol |
Link |
|
IFN-g |
Plasmodium chabaudi chabaudi AS |
DBA/2 |
anti-IFN-g |
yes |
yes |
N.I. |
N.I. |
Increased peak |
Similar body weight and body temperature |
Cross et al., 1998, Exp Parasitol |
Link |
|
IFN-g |
Plasmodium chabaudi chabaudi AS |
B10.D2 |
anti-IFN-g |
no |
no |
N.I. |
N.I. |
Increased peak |
↓ body weight and body temperature |
Cross et al., 1998, Exp Parasitol |
Link |
|
IFN-g |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
anti-IFN-g |
no |
no |
N.I. |
N.I. |
Similar |
Similar iNOS mRNA expression in spleen 7 days p.i.. similar NO3- levels in serum 7 days p.i.; similar spleen weight 7 days p.i. |
Jacobs et al. 1996, Infect Immun |
Link |
|
IFN-g |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
anti-IFN-g |
no |
no |
N.I. |
N.I. |
Increased peak |
N.I. |
Meding et al., 1990, Infect Immun |
Link |
|
IFN-g |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
rIFN-g |
no |
no |
N.I. |
N.I. |
Decreased peak |
N.I. |
Meding et al., 1990, Infect Immun |
Link |
|
IFN-g |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
IFN-g -/- |
no |
♂ 100 %; ♀ 40 % |
N.I. |
N.I. |
♂: increased peak ♀: increased peak and increased recrudescences |
↓serum TNF-a, IL-12p70 and NO; ↓ splenic macrophages, NK cells and T cells (only in ♂); similar splenic B cells and Mac-1+ cells; ↓parasite-specific IgM, IgG2a, IgG3 and ↑IgG1; similar TNF-a, IL-4 and ↑ IL-10 production by spleen cells after in vitro stimulation with pRBC |
Su et al., 2000, Infect Immunol |
Link |
|
IFN-g |
Plasmodium yoelii 17XL |
C57BL/6J |
anti-IFN-g |
yes |
yes |
N.I. |
N.I. |
Similar |
Earlier death (days) |
Kobayashi et al., 2000, J Vet Med Sci |
Link |
|
IFN-g |
Plasmodium yoelii 17XL |
CBA/J |
rIFN-g |
no |
no |
N.I. |
N.I. |
Decreased peak |
No effect on the outcome of infection |
Shear et al., 1989, J Immunol |
Link |
|
IFN-g |
Plasmodium yoelii 17XL |
SW |
rIFN-g |
yes |
yes |
N.I. |
N.I. |
Delayed onset and decreased peak |
Prolonged survival (days, dose-dependent); ↑ phagocytic activity and H2O2 production by peritoneal macrophages that was partially abrogated after pretreatment with anti-IFN-g |
Shear et al., 1989, J Immunol |
Link |
|
IFN-g |
Plasmodium yoelii 17XL |
BALB/cByJ |
rIFN-g |
yes |
yes |
N.I. |
N.I. |
Delayed onset and decreased peak |
Prolonged survival (days, dose-dependent) |
Shear et al., 1989, J Immunol |
Link |
|
IFN-g |
Plasmodium yoelii 17XNL |
SW |
rIFN-g |
no |
no |
N.I. |
N.I. |
Similar |
No effect on the outcome of infection |
Shear et al., 1989, J Immunol |
Link |
|
IFN-g |
Plasmodium yoelii 17XNL |
BALB/cByJ |
rIFN-g |
no |
no |
N.I. |
N.I. |
Decreased peak |
No effect on the outcome of infection |
Shear et al., 1989, J Immunol |
Link |
|
IFN-g |
Plasmodium yoelii 17XNL |
CBA/J |
rIFN-g |
no |
no |
N.I. |
N.I. |
Similar |
No effect on the outcome of infection |
Shear et al., 1989, J Immunol |
Link |
|
IFN-g |
Plasmodium yoelii 17XNL |
129/Ola x C57BL/6 (WT = 129/Ola) |
IFN-g -/- |
no |
no |
N.I. |
N.I. |
No parasite clearance in 30 days |
N.I. |
Van der heyde et al., 1997, Exp Parasitol |
Link |
|
IFN-g/CTLA-4 |
Plasmodium berghei ANKA |
C57BL/6 |
IFN-g -/- + anti-CTLA-4 |
yes |
yes |
No CM |
No CM |
N.I. |
N.I. |
Jacobs et al., 2002, J Immunol |
Link |
|
IFN-g/CTLA-4 |
Plasmodium berghei ANKA |
C57BL/6 |
IFN-g -/- + anti-CTLA-4 |
yes |
yes |
Moderate liver pathology |
Moderate liver pathology |
N.I. |
↓ serum AST and ALT levels compared to anti-CTLA-4-treated WT (similar compared to untreated WT mice); ↓ CD4+ T cells in liver compared to untreated and anti-CTLA-4-treated WT mice (similar compared to untreated IFN-g -/-) |
Jacobs et al., 2004, Eur J Immunol |
Link |
|
IFN-gR |
Plasmodium berghei ANKA |
129/Sv/Ev x C57BL/6 (WT = 129 Sv/Ev) |
IFN-gR -/- |
yes |
yes |
CM (60-100% depending on the parasite dose used) |
No CM |
Similar/higher depending on the parasite dose used |
No neurological symptoms; similar anemia; ↑ serum IFN-g, TNF-a; similar IFN-g protein expression in the brain and ↑ IFN-g protein expression in the spleen; ↓ TNF-a mRNA expression in the spleen and brain; ↓ TNF-a protein expression in the brain; ↓ IL-6 and IL-10 mRNA expression in the brain; similar IL-6 mRNA expression in the spleen; similar NO in serum, brain and spleen |
Amani et al., 2000, Eur J Immunol |
Link |
|
IFN-gR |
Plasmodium berghei ANKA |
DBA/1 |
IFN-gR -/- |
yes |
yes |
CM (89%) |
No CM |
Similar |
↓ mRNA expression of chemokines (MCP-1, RANTES, MIP-1b, MIG, IP-10, I-TAC) and adhesion molecules (ICAM-1, LFA-1, P-selectin, VCAM-1), ↑ mRNA expression of P-selectin and abrogated IP-10 protein expression in the brain |
Van den Steen et al., 2008, Eur J Immunol |
Link |
|
IFN-gR |
Plasmodium chabaudi adami 556KA |
129/Sv/Ev x C57BL/6 |
IFN-gR -/- |
no |
no |
N.I. |
N.I. |
Delayed peak |
N.I. |
Tsuji et al., 1995, J Immunol |
Link |
|
IFN-gR |
Plasmodium chabaudi AS |
C57BL/6 |
IFN-gR -/- |
No |
N.I. |
N.I. |
N.I. |
Increased on day 9 |
↓ sequestration in livers (day 5 and day 9 p.i.), but not in spleen or lungs; ↓ serum ALT levels; similar numbers of IFN-g+ lymphocytes in the lungs 9 days p.i.; similar IgM and albumin levels in BAL fluid; similar tubular dilatation, plasma creatinine levels and plasma urea levels |
Brugat et al., 2013, Cell Microbiol |
Link |
|
IFN-gR |
Plasmodium chabaudi chabaudi AS |
129/Sv/Ev x C57BL/6 |
IFN-gR -/- |
no |
77% |
N.I. |
N.I. |
Second peak as high as first peak |
First peak:↑ parasite-specific IgM, similar IgG1 and ↓ IgG2a, IgG2b and IgG3; ↓ serum NO3-; ↑ leukocytosis; similar anemia; ↓ splenomegaly; second peak: similar serum NO3-; ↑ leukocytosis and anemia; similar splenomegaly; ↑ parasite-specific IgM and IgG1 after second peak; resistant to secondary infection |
Favre et al., 1997, Parasite Immunol |
Link |
|
IFN-gR |
Plasmodium chabaudi chabaudi AS |
129/Sv/Ev x C57BL/6 |
IFN-gR -/- |
no |
no |
Anemia |
Anemia |
Prolonged acute parasitemia with second peak |
Similar hypoglycaemia and weight loss; more pronounced hypothermia |
Li et al., 1999, Infect Immun |
Link |
|
IFN-gRa |
Plasmodium berghei ANKA |
129P2Sv/Ev |
IFN-gRa -/- |
yes |
yes |
CM (60-100%) |
No CM |
Similar |
↓ total leukocyte numbers and CD8+ T cells and similar numbers of macrophages, neutrophils and CD4+ T cells in the brain at the time of CM; ↑ numbers of total leukocytes, macrophages, CD4+ and CD8+ T cells and ↓ numbers of neutrophils in the lungs at the time of CM; no pulmonary edema; ↓ mRNA expression of MIP-1a/CCL3, RANTES/CCL5, IP-10/CXCL10, CCR2 and CCR1 and similar MCP-1/CCL2, CCR5 and CXCR3 in the brain; ↑ mRNA expression of MCP-1/CCL2 and IP-10/CXCL10, ↓ CCR2 and CXCR3 and similar MIP-1a/CCL3, RANTES/CCL5, CCR5 and CCR1 in the lungs; ↑ mRNA expression of MIP-1a/CCL3, IP-10/CXCL10, CCR5 and CXCR3 and similar MCP-1/CCL2, RANTES/CCL5, CCR2 and CCR1 in the spleen |
Belnoue et al., 2008, Parasite Immunol |
Link |
|
IFNabR |
Plasmodium chabaudi AS |
129 Sv/Ev |
IFNabR -/- |
no |
no |
N.I. |
N.I. |
Similar |
Increased weight loss and hypothermia |
Voisine et al., 2010, Int J Parasitol |
Link |
|
IFNaR1 |
Plasmodium berghei ANKA |
C57BL/6 |
IFNaR1 -/- |
yes |
yes |
CM (~90%) |
CM (~25%) |
Increased on day 6-7 |
Prolonged survival (2-3 weeks); no neurological symptoms; no BBB leakage; less intravascular accumulation of mononuclear cells; no endothelial cell disruption or hemorrhagic lesions; similar parasite accumulation and CD3 expression in the brain; delayed kinetics of TNF and IL-10 mRNA expression in the brain; ↓ numbers of CD8+, CD8+GrB+, and CD8+IFN-g+ cells in the spleen at baseline in uninfected mice, similar numbers in the spleen at day 5 p.i., and ↓ numbers in the brain at day 6 p.i. |
Ball et al., 2013, J Immunol |
Link |
|
IFNaR1 |
Plasmodium berghei ANKA |
IFNaR1 |
+ adoptive transfer of total splenocytes from C57BL/6 mice that had recieved irradiated pRBCs |
yes |
yes |
CM (~25%) |
CM (~75%) |
N.I. |
N.I. |
Ball et al., 2013, J Immunol |
Link |
|
IFNaR1 |
Plasmodium berghei ANKA |
IFNaR1 -/- |
+ adoptive transfer of splenic CD8+ cells from C57BL/6 mice that had recieved irradiated pRBCs |
yes |
yes |
No CM |
CM (100%) |
Similar |
BBB leakage (↑ compared to infected IFNaR1-/- that not recieved cells); CD8+, CD8+GrB+, and CD8+IFN-g+ cells were found in the brain |
Ball et al., 2013, J Immunol |
Link |
|
IFNaR1 |
Plasmodium berghei ANKA |
IFNaR1 -/- |
+ adoptive transfer of splenocytes depleted of CD8+ cells from C57BL/6 mice that had recieved irradiated pRBCs |
yes |
yes |
No CM |
No CM |
Similar |
No BBB leakage (similar compared to infected IFNaR1-/- that not recieved cells); CD8+, CD8+GrB+, and CD8+IFN-g+ cells were found in the brain |
Ball et al., 2013, J Immunol |
Link |
|
IFNaR1 |
Plasmodium berghei ANKA |
IFNaR1 -/- |
+ adoptive transfer of splenic CD8+ cells from IFNaR1-/- mice that had recieved irradiated pRBCs |
yes |
yes |
No CM |
CM (~25%) |
Similar |
N.I. |
Ball et al., 2013, J Immunol |
Link |
|
IL-10 |
Plasmodium berghei ANKA |
CBA/J |
rIL-10 |
yes |
yes |
CM (100%) |
CM (38.6 %) |
similar |
Prolonged survival (days-weeks); no neurological symptoms; similar TNF-a |
Kossodo et al., 1997, Immunology |
Link |
|
IL-10 |
Plasmodium berghei ANKA |
BALB/c |
anti-IL-10 |
yes |
yes |
HP&A |
HP&A |
similar |
Similar mortality; ↑ TNF-a |
Kossodo et al., 1997, Immunology |
Link |
|
IL-10 |
Plasmodium berghei ANKA |
129 x C57BL/6 |
IL-10 -/- |
yes |
yes |
CM (89%) |
CM (100%) |
N.I. |
N.I. |
Yañez et al., 1996, J Immunol |
Link |
|
IL-10 |
Plasmodium berghei NK65 |
C57BL/6 |
IL-10 -/- |
yes |
yes |
Liver pathology |
↑ Liver pathology |
Decreased |
Similar weight loss (↓ compared to IL-27R -/- mice); ↑ liverpathology (similar compared to IL-27R -/- mice); ↑ numbers of total splenic CD4+ T cells and similar numbers of liver-infiltrating CD4+ T cells 14 days p.i. (↑ numbers of total splenic CD4+ T cells and ↓ numbers of liver-infiltrating CD4+ T cells compared to IL-27R -/- mice) |
Findlay et al., 2010; J immunol |
Link |
|
IL-10 |
Plasmodium chabaudi adami 556KA |
129/Ola x C57BL/6 |
IL-10 -/- |
no |
no |
N.I. |
N.I. |
Similar |
Similar number of splenic gd T cells |
Van der heyde et al., 1996, J Leukoc Biol |
Link |
|
IL-10 |
Plasmodium chabaudi adami 556KA |
129/Ola x C57BL/6 (WT = 129/Ola) |
IL-10 -/- |
no |
no |
N.I. |
N.I. |
Similar |
N.I. |
Van der heyde et al., 1997, Exp Parasitol |
Link |
|
IL-10 |
Plasmodium chabaudi AS |
C57BL/6 |
IL-10 -/- |
No |
N.I. |
N.I. |
N.I. |
Similar |
↑ sequestration in the spleen (day 9 p.i.) and in the liver (day 5 and day 9 p.i. although not significantly), but not in the lungs; similar serum ALT levels; ↑ numbers of IFN-g+ lymphocytes in the lungs 9 days p.i.; ↑ IgM and albumin levels in BAL fluid; ↑ tubular dilatation, plasma creatinine levels and plasma urea levels |
Brugat et al., 2013, Cell Microbiol |
Link |
|
IL-10 |
Plasmodium chabaudi chabaudi AS |
129/Sv x C57BL/6 |
IL-10 -/- |
no |
♀ 50 %; ♂ no |
Anemia |
Anemia |
Similar |
↑ mortality;↑ hypothermia, hypoglycemia and weight loss in ♀ |
Li et al., 1999, Infect Immun |
Link |
|
IL-10 |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
IL-10 -/- |
no |
♀ 30 %; ♂ no |
Anemia |
Anemia |
Similar |
↑ mortality;↑ hypothermia, hypoglycemia and weight loss in ♀; ↑ plasma TNF-a and IFN-g; ↑ TNF-a, IFN-g, IL-12p40 and NOS2 mRNA in spleen |
Li et al., 1999, Infect Immun |
Link |
|
IL-10 |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
IL-10 -/- |
no |
♀ 66 % |
Anemia |
N.I. |
Similar |
↑ mortality; surviving mice had ↓ hypothermia and hypoglycaemia, similar anemia and weight loss; ↑ serum TGF-b |
Li et al., 2003, Infect Immun |
Link |
|
IL-10 |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
IL-10 -/- |
no |
♀ 70 % |
Anemia |
CM (♀ 70 %) |
Similar |
↑ parasite sequestration; cerebral edema and hemorrhages (CM?) |
Sanni et al., 2004, Infect Immun |
Link |
|
IL-10 |
Plasmodium yoelii 17XL |
C57BL/6J |
anti-IL-10 |
yes |
40% (at the end of observation day 25) |
N.I. |
N.I. |
Similar |
N.I. |
Kobayashi et al., 2000, J Vet Med Sci |
Link |
|
IL-10 |
Plasmodium yoelii 17XL |
C57BL/6 |
anti-IL-10R |
yes |
yes |
N.I. |
N.I. |
Similar |
↑ plasma IFN-g |
Omer et al., 2003, J Immunol |
Link |
|
IL-10 |
Plasmodium yoelii 17XNL |
129/Ola x C57BL/6 (WT = 129/Ola) |
IL-10 -/- |
no |
not in 30 days |
N.I. |
N.I. |
Similar |
N.I. |
Van der heyde et al., 1997, Exp Parasitol |
Link |
|
IL-10/CD25 |
Plasmodium berghei ANKA |
C57BL/6 |
IL-10 -/- + anti-CD25 |
yes |
yes |
CM (100%) |
CM (100%) |
N.I. |
Delayed mortality (1-2 days); similar neurologic symptoms |
Amante et al., 2007, Am J Pathol |
Link |
|
IL-10/IFN-g |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
IL-10 -/- + anti-IFN-g |
no |
no |
Anemia |
Anemia |
Increased recrudescences |
Similar hypothermia, hypoglycemia and weight loss compared to IL-10-/- mice |
Li et al., 1999, Infect Immun |
Link |
|
IL-10/IFN-g |
Plasmodium chabaudi chabaudi AS |
129/Sv x C57BL/6 |
IL-10-/- x IFN-gR-/- |
no |
no |
Anemia |
Anemia |
Prolonged acute parasitemia and prominent second peak |
Similar hypothermia, hypoglycemia, weight loss and plasma TNF-a compared to IL-10-/- mice |
Li et al., 1999, Infect Immun |
Link |
|
IL-10/TGF-b |
Plasmodium chabaudi chabaudi AS |
IL-10 -/- |
anti-TGF-b |
♀ 66 % |
♀ yes (100%) |
N.I. |
N.I. |
Similar |
↑ anemia and hypoglycemia, similar hypothermia and weight loss; ↑ plasma IFN-g and TNF-a |
Li et al., 2003, Infect Immun |
Link |
|
IL-10/TNF-a |
Plasmodium chabaudi chabaudi AS |
IL-10 -/- |
anti-TNF-a |
♀ 66 % |
♀ no |
N.I. |
N.I. |
Increased recrudescences |
↓ hypothermia, anemia, weight loss and similar hypoglycemia; similar plasma IFN-g |
Li et al., 2003, Infect Immun |
Link |
|
IL-10/TNF-a |
Plasmodium chabaudi chabaudi AS |
IL-10 -/- |
anti-TNF-a |
♀ 70 % |
no |
CM (♀ 70 %) |
N.I. |
N.I. |
↓ cerebral edema and hemorrhages (50 %) |
Sanni et al., 2004, Infect Immun |
Link |
|
IL-12 |
Plasmodium berghei ANKA |
C57BL/6 |
IL-12 -/- |
N.I. |
N.I. |
N.I. |
N.I. |
N.I. |
Similar ICAM-1 protein expression in the brain; ↓ ICAM-1 protein expression in the lung |
Bauer et al., 2002, Microcirculation |
Link |
|
IL-12 |
Plasmodium berghei ANKA |
C57BL/6 |
rIL-12 |
yes |
20% (at the end of observation day 23) |
N.I. |
N.I. |
Delayed onset and decreased peak |
Prolonged survival (1-2 weeks); ↑ NOS2 mRNA expression in brain 11 days p.i., in kidneys 4 days p.i. and in liver and spleen; ↑ NO2- and IFN-g production by ConA stimulated spleen cells and in serum; ↑ IFN-g mRNA expression in liver, spleen and kidney; ↑ liver pathology; ↓ IL-10 and similar TNF-a mRNA in spleen; ↑ NOS2 and similar IFN-g in brain and spleen |
Tan et al., 1999, Infect Immun |
Link |
|
IL-12 |
Plasmodium berghei ANKA |
C57BL/6 |
rIL-12 |
yes |
20% (at the end of observation day 23) |
N.I. |
N.I. |
Delayed onset and decreased peak which declined partly with subsequent increase |
Prolonged survival (1-2 weeks); IL-10 mRNA was ↓ on day 11 after infection in liver and spleen and ↓ on day 8, 11 in the kidneys; similar TNF-a expression in liver, spleen and kidneys |
Tan et al., 2000, Parasite Immunology |
Link |
|
IL-12 |
Plasmodium berghei XAT |
CBA/JNCrj |
anti-IL-12 |
no |
yes |
N.I. |
N.I. |
Increased and no clearance |
↓ IFN-g and NOS2 and similar IL-4 and IL-10 mRNA expression in the spleen; ↓ IFN-g protein production by spleen cells |
Yoshimoto et al., 1998, J Infect Dis |
Link |
|
IL-12 |
Plasmodium berghei XAT |
CBA/JNCrj |
rIL-12 |
no |
no |
N.I. |
N.I. |
Delayed onset and no second peak |
↑ IFN-g and IL-10 and ↓ IL-4 mRNA expression in the spleen; ↑ IFN-g production by unstimulated, ConA and anti-CD3 stimulated spleen cells; ↓ IL-4 production by ConA and anti-CD3 stimulated spleen cells |
Yoshimoto et al., 1998, J Infect Dis |
Link |
|
IL-12 |
Plasmodium chabaudi chabaudi AS |
A/J |
rIL-12 |
yes |
no |
N.I. |
N.I. |
Spontaneous decline |
↑ NKCC by spleen cells (maximal NKCC activity enhancement after 2 days rIL-12 treatment and ↓ NKCC activity enhancement after longer rIL-12 treatment); ↑ splenic cellularity (similar to infected C57BL/6 mice): ↑ number of CD3+, B220+ and Mac-1+ spleen cells; ↑ IFN-g and similar TNF-a production by splenic NK cells |
Mohan et al., 1997, J Immunol |
Link |
|
IL-12 |
Plasmodium chabaudi chabaudi AS |
A/J |
rIL-12 |
yes |
yes |
Severe anemia |
Severe anemia |
Similar |
Similar anemia and reticulocytosis; rIL-12-treated splenocytes produced similar amounts of IFN-g after parasite-antigen stimulation compared to untreated splenocytes |
Mohan et al., 1999, Infect Immun |
Link |
|
IL-12 |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
rIL-12 |
no |
60% |
N.I. |
N.I. |
Decreased peak |
N.I. |
Stevenson et al., 1995, J Immunol |
Link |
|
IL-12 |
Plasmodium chabaudi chabaudi AS |
A/J |
rIL-12 |
yes |
25% |
N.I. |
N.I. |
Decreased peak and spontaneous decline |
Dose-dependant survival; ↑ production of IFN-g and similar production of IL-4 and IL-5 by spleen cells 7 days p.i.; ↑ serum IFN-g, TNF-a and NO3- |
Stevenson et al., 1995, J Immunol |
Link |
|
IL-12/CD4 |
Plasmodium chabaudi chabaudi AS |
A/J |
rIL-12 + anti-CD4 |
yes |
yes |
N.I. |
N.I. |
Similar |
N.I. |
Stevenson et al., 1995, J Immunol |
Link |
|
IL-12/chloroquine |
Plasmodium chabaudi chabaudi AS |
A/J |
rIL-12 + chloroquine |
yes |
no |
Severe anemia |
None |
Decreased peak |
↓ anemia, ↑ erythropoiesis and reticulocytosis; combined therapy induced ↑ IFN-g production by parasite antigen stimulated splenocytes; resistant to secondary infection due to ↑ parasite-specific IgG levels |
Mohan et al., 1999, Infect Immun |
Link |
|
IL-12/CTLA-4 |
Plasmodium berghei ANKA |
C57BL/6 |
IL-12p40 -/- + anti-CTLA-4 |
yes |
yes |
No CM |
No CM |
N.I. |
N.I. |
Jacobs et al., 2002, J Immunol |
Link |
|
IL-12/CTLA-4 |
Plasmodium berghei ANKA |
C57BL/6 |
IL-12p40 -/- + anti-CTLA-4 |
yes |
yes |
Moderate liver pathology |
Moderate liver pathology |
N.I. |
↓ serum AST and ALT levels compared to anti-CTLA-4-treated WT (similar compared to untreated WT mice); ↓ CD4+ T cells in liver compared to anti-CTLA-4-treated WT mice (similar compared to IL-12 -/- and untreated WT mice) |
Jacobs et al., 2004, Eur J Immunol |
Link |
|
IL-12/IFN-g |
Plasmodium berghei XAT |
CBA/JNCrj |
rIL-12 + anti-IFN-g |
no |
yes |
N.I. |
N.I. |
Increased and no clearance |
N.I. |
Yoshimoto et al., 1998, J Infect Dis |
Link |
|
IL-12/IFN-g |
Plasmodium chabaudi chabaudi AS |
A/J |
rIL-12 + anti-IFN-g |
yes |
50% |
N.I. |
N.I. |
Delayed peak (days) and increased recrudescences |
N.I. |
Stevenson et al., 1995, J Immunol |
Link |
|
IL-12/IFN-g/TNF-a |
Plasmodium chabaudi chabaudi AS |
A/J |
rIL-12 + anti-IFN-g + anti-TNF-a |
yes |
yes |
N.I. |
N.I. |
Delayed peak (days) and increased recrudescences |
N.I. |
Stevenson et al., 1995, J Immunol |
Link |
|
IL-12/NK cells |
Plasmodium chabaudi chabaudi AS |
A/J |
rIL-12 + anti-asialo GM1 |
yes |
yes |
N.I. |
N.I. |
Increased peak |
N.I. |
Mohan et al., 1997, J Immunol |
Link |
|
IL-12/NOS2 |
Plasmodium chabaudi chabaudi AS |
A/J |
rIL-12 + NOS2 inhibitor |
yes |
54-67% |
N.I. |
N.I. |
Similar |
N.I. |
Stevenson et al., 1995, J Immunol |
Link |
|
IL-12/TNF-a |
Plasmodium chabaudi chabaudi AS |
A/J |
rIL-12 + anti-TNF-a |
yes |
yes |
N.I. |
N.I. |
Similar |
N.I. |
Stevenson et al., 1995, J Immunol |
Link |
|
IL-12p40 |
Plasmodium berghei ANKA |
C57BL/6 |
IL-12p40 -/- |
yes |
~85% (at the end of observation day 20) |
CM (100%) |
CM (~85% at the end of observation day 20) |
N.I. |
N.I. |
Berghout et al., 2013, PLoS Pathog |
Link |
|
IL-12p40 |
Plasmodium berghei NK65 |
C57BL/6J |
IL-12 -/- |
yes |
N.I. |
Liver pathology |
No liverpathology |
Similar |
↓ GPT (ALT) serum levels; no liver injury; similar infiltration of lymphocytes in liver |
Adachi et al., 2001, J Immunol |
Link |
|
IL-12p40 |
Plasmodium berghei NK65 |
C57BL/6 |
anti-IL-12p40 |
yes |
yes |
Liver pathology |
Liver pathology |
Similar |
Prolonged survival (~ 1 week); ↓serum AST and ALT; ↓ liver injury; ↓ in vitro production of IFN-g by spleen and liver cells |
Yoshimoto et al., 1998, J Immunol |
Link |
|
IL-12p40 |
Plasmodium chabaudi chabaudi AS |
129/Sv x C57BL/6J |
IL-12p40 -/- |
no |
no |
N.I. |
N.I. |
Increased first peak and developed a prominent second peak |
Similar protection during second challenge; first peak (day 7): no NO or IFN-g production by spleen cells, no NO secretion after IFN-g stimulation of spleen cells; second peak (day 15): no NO production by spleen cells, similar NO secretion after IFN-g stimulation of spleen cells;↓ NO and ↑ TGF-b1 production by macrophages after stimulation with pRBCs or rIFN-g; ↓ internalization of pRBCs coated with immune serum antibodies by macrophages |
Bastos et al., 2002, J Interferon Cytokine Res |
Link |
|
IL-12p40 |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
anti-IL-12p40 |
no |
no |
N.I. |
N.I. |
Increased peak and increased recrudescences |
N.I. |
Stevenson et al., 1995, J Immunol |
Link |
|
IL-12p40 |
Plasmodium chabaudi chabaudi AS |
129/Sv x C57BL/6J |
IL-12p40 -/- |
no |
♀ no; ♂ 40 % |
Anemia |
Anemia |
Increased peak and increased recrudescences, no parasite clearance 40 days p.i. |
↓ hematocrit levels and body weight; similar splenomegaly; ↓ serum IFN-g ; ↓ IFN-g production by splenic NK cells; ↓ NK cell cytotoxicity; ↑ IL-10, similar TNF-a and ↓ IFN-g production by spleen cells 7 days p.i.; similar IL-4 production by spleen cells 21 days p.i.; ↓ serum parasite-specific total Ig, IgM and IgG2a,↑ IgG1 15 and 21 days p.i.; no protection against challenge infection; ↓ IgG2a and IgG3, ↑ IgG1 and similar IgG2b 7 days after challenge infection; KO immune sera or IgG2a depleted WT immune serum did not protect susceptible A/J mice |
Su et al., 2002, J Immunol |
Link |
|
IL-12p40 |
Plasmodium chabaudi chabaudi AS |
129/Sv x C57BL/6J |
IL-12p40 -/- + rIL-12 |
no |
no |
Anemia |
Anemia |
Increased recrudescences, but less than without rIL-12 |
Similar serum levels of parasite-specific total Ig, IgM and IgG2a, ↓ IgG1; similar protection against challenge infection; similar IgG2a, IgG3, IgG1 and IgG2b 7 days after challenge infection |
Su et al., 2002, J Immunol |
Link |
|
IL-15 |
Plasmodium chabaudi chabaudi AS |
C57BL/6 |
IL-15 -/- |
no |
10% |
N.I. |
N.I. |
Increased and persistent low parasitemia |
↓serum IFN-g, TNF-a, IL-12p70 and similar IL-10; ↑ number of apoptotic NK cells 5 days p.i.; ↓ NK cell cytotoxicity and in vitro IFN-g production; ↓ parasite-specific total IgG, IgG1, IgG2a, IgG2b, IgG3 and IgM |
Ing et al., 2005, Infect Immun |
Link |
|
IL-17 |
Plasmodium berghei ANKA |
C57BL/6 |
IL-17-/- (17KO) |
yes |
yes |
CM (80%) |
CM (80%) |
Similar |
Similar neurological symptoms |
Ishida et al., 2010, Biochem Biophys Res Commun |
Link |
|
IL-18 |
Plasmodium berghei ANKA |
BALB/c |
IL-18 -/- |
yes |
yes |
N.I. |
N.I. |
N.I. |
Earlier death (~ 1 week) |
Singh et al., 2002, J Immunol |
Link |
|
IL-18 |
Plasmodium berghei ANKA |
BALB/c |
anti-IL-18 |
yes |
yes |
N.I. |
N.I. |
N.I. |
Earlier death (~ 1 week) |
Singh et al., 2002, J Immunol |
Link |
|
IL-18 |
Plasmodium berghei ANKA |
C57BL/6 |
rIL-18 |
yes |
yes |
N.I. |
N.I. |
N.I. |
Prolonged survival (~ 2 weeks) |
Singh et al., 2002, J Immunol |
Link |
|
IL-18 |
Plasmodium berghei ANKA |
BALB/c |
rIL-18 |
yes |
yes |
N.I. |
N.I. |
Delayed onset |
Prolonged survival (days – weeks: dose-dependent) due to ↑ serum IFN-g production; ↓ liver and spleen pathology |
Singh et al., 2002, J Immunol |
Link |
|
IL-18 |
Plasmodium berghei NK65 |
C57BL/6 |
IL-18 -/- |
yes |
yes |
Liver pathology |
Liver pathology |
Similar |
Similar GPT (ALT) serum levels and liver injury |
Adachi et al., 2001, J Immunol |
Link |
|
IL-18 |
Plasmodium yoelii 17XNL |
C57BL/6 |
IL-18 -/- |
no |
no |
N.I. |
N.I. |
Increased |
N.I. |
Cramer et al., 2008, Microbes Infect |
Link |
|
IL-18 |
Plasmodium yoelii 265 |
BALB/c |
rIL-18 |
20% |
0-20% (dose-dependent) |
N.I. |
N.I. |
Delayed onset and decreased peak (dose-dependent) |
Dose-dependant survival due to ↑ serum IFN-g production; ↓ liver and spleen pathology |
Singh et al., 2002, J Immunol |
Link |
|
IL-18/CTLA-4 |
Plasmodium berghei ANKA |
C57BL/6 |
IL-18 -/- + anti-CTLA-4 |
yes |
yes |
Moderate liver pathology |
Moderate liver pathology |
N.I. |
↓ serum AST compared to anti-CTLA-4-treated WT and similar to untreated WT; similar serum ALT compared to anti-CTLA-4-treated WT mice and ↑ compared to untreated WT; ↑ CD4+ T cells in liver compared to untreated WT and untreated IL-18 -/- mice (similar compared to anti-CTLA-4-treated WT mice) |
Jacobs et al., 2004, Eur J Immunol |
Link |
|
IL-1a |
Plasmodium berghei K173 |
C57BL/6J |
rIL-1a |
yes |
N.I. |
CM (100%) |
CM (22%) |
Delayed |
↓ CM incidence only when administered for 6 consecutive days and dose-dependent; no cerebral hemorrhages; no decrease in body temperature; no differences in erythropoiesis |
Curfs et al., 1990, J Exp Med |
Link |
|
IL-1a |
Plasmodium berghei K173 |
C57BL/6J-nu |
rIL-1a |
yes |
N.I. |
N.I. |
N.I. |
Similar |
N.I. |
Curfs et al., 1990, J Exp Med |
Link |
|
IL-1a/IFN-g |
Plasmodium berghei K173 |
C57BL/6J |
rIL-1a + anti-IFN-g |
yes |
N.I. |
CM |
No CM |
Similar |
N.I. |
Curfs et al., 1990, J Exp Med |
Link |
|
IL-1b |
Plasmodium berghei K173 |
C57BL/6J |
rIL-1b |
yes |
N.I. |
CM |
No CM |
Delayed |
N.I. |
Curfs et al., 1990, J Exp Med |
Link |
|
IL-1R |
Plasmodium berghei ANKA |
N.I. |
IL-1R -/- |
yes |
yes |
CM (100%) |
CM (100%) |
N.I. |
N.I. |
Reimer et al., 2010, Eur J Immunol |
Link |
|
IL-1R |
Plasmodium yoelii 17XNL |
C57BL/6 |
IL-1R -/- |
no |
no |
N.I. |
N.I. |
Increased |
N.I. |
Cramer et al., 2008, Microbes Infect |
Link |
|
IL-2 |
Plasmodium berghei ANKA |
129 x C57BL/6 |
IL-2 -/- |
yes |
yes |
CM (70%) |
No CM |
N.I. |
N.I. |
Yañez et al., 1996, J Immunol |
Link |
|
IL-2 |
Plasmodium chabaudi adami 556KA |
129/Ola x C57BL/6 (WT = 129/Ola) |
IL-2 -/- |
no |
no |
N.I. |
N.I. |
Delayed clearance |
N.I. |
Van der heyde et al., 1997, Exp Parasitol |
Link |
|
IL-2 |
Plasmodium chabaudi chabaudi AS |
129 x C57BL/6 |
IL-2 -/- |
no |
25% |
N.I. |
N.I. |
Delayed peak and delayed clearance |
↑ Mac-1+, ↓ CD3+ (especially CD8+ and gd+) and B cells in the spleen |
Seixas et al., 2002, Parasite Immunol |
Link |
|
IL-2 |
Plasmodium yoelii 17XL |
DBA/2 |
rIL-2 |
no |
yes |
None |
CM (100%) |
Similar |
Splenocytes 3 days p.i.: ↓ IFN-g , ↑ NO and IL-10; splenocytes 6 days p.i.: similar IFN-g and IL-10, ↑ NO; cerebral accumulation of pRBCs and CD25+ ICAM-1+ T cells (mostly gd T cells) |
Haque et al., 2001, Am J Pathol |
Link |
|
IL-2 |
Plasmodium yoelii 17XNL |
BALB/c |
rIL-2 |
no |
70% |
N.I. |
N.I. |
Decreased peak |
Induction of IL-2, IFN-g, IL-6 and IL-10 mRNA expression in splenic cells; ↑ CD3 or ConA-induced lymphocyte proliferation |
Lucas et al., 1996, C R Acad Sci III |
Link |
|
IL-2 |
Plasmodium yoelii 17XNL |
129/Ola x C57BL/6 (WT = 129/Ola) |
IL-2 -/- |
no |
no |
N.I. |
N.I. |
Delayed clearance |
N.I. |
Van der heyde et al., 1997, Exp Parasitol |
Link |
|
IL-2/B cells |
Plasmodium chabaudi chabaudi AS |
129 x C57BL/6 |
IL-2 -/- x m-MT |
no |
yes |
N.I. |
N.I. |
Delayed peak |
↑ % of Mac-1+ and CD4+ cells and ↓ % of CD8, gd and B cells in the spleen |
Seixas et al., 2002, Parasite Immunol |
Link |